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The sterol regulatory element-binding factor-2 (SREBF2) gene is a bifunctional locus encoding SREBP-2,
a well-known transcriptional regulator of genes involved in cholesterol biosynthesis, and microRNA-33a,
which has recently been shown to reduce expression of proteins involved in export of cholesterol and
b-oxidation of fatty acids, thus adding an unexpected layer of complexity and fine-tuning to regulation of lipid
homeostasis.Introduction
Fatty acids, cholesterol, and their lipid derivatives play essential
roles in normal cellular function and serve as structural compo-
nents, signaling molecules, and/or as storage forms of energy
(Maxfield and Tabas, 2005). In multicellular organisms, cellular
lipid metabolism is regulated to match the needs both of indi-
vidual cells and of the entire organism. A sedentary lifestyle
coupled with overconsumption of calories, as common with
a western diet, stresses the regulatory circuits of lipid homeo-
stasis. Although lipids are essential for life, their excessive accu-
mulation and/or abnormal distribution lead to significant health
issues such as type 2 diabetes and atherosclerosis, which are
responsible for significant morbidity and mortality. As such,
understanding the regulation of lipidmetabolismmay help define
novel targets for future therapeutic intervention. Lipid metabo-
lism is regulated at many levels, including transcriptional control
of fatty acid synthesis, storage and oxidation by peroxisome
proliferator-activated receptors, and cholesterol homeostasis
by liver X receptors (Pyper et al., 2010; Zhao and Dahlman-
Wright, 2010). Several recent publications point to an important
role of miRNAs (Gerin et al., 2010b; Horie et al., 2010; Kru¨tzfeldt
et al., 2005; Marquart et al., 2010; Najafi-Shoushtari et al., 2010;
Rayner et al., 2010). Here, we review how cholesterol and fatty
acid homeostasis is regulated by products of the SREBF bifunc-
tional loci, which encode SREBP transcription factors and the
microRNA (miR)-33 family.
SREBPs Regulate Cellular Lipid Homeostasis
Sterol regulatory element-binding proteins (SREBPs) act as
a central hub in the regulation of cellular lipid levels. These basic
helix-loop-helix-leucine zipper transcription factors bind to
specific cis elements and regulate transcription of target genes,
whose products play key roles in lipid metabolism. They are
encoded by genes that carry the name sterol regulatory
element-binding factor (SREBF). While lower organisms possess
one SREBF gene, vertebrate genomes contain SREBF1 and
SREBF2, which code for SREBP-1 and SREBP-2, respectively.
The locus-encoding SREBP-1 gives rise to two major mRNA
species, SREBP-1a and SREBP-1c, which are transcribed fromdistinct promoters (Shimomura et al., 1997). SREBP-1a,
SREBP-1c, and SREBP-2 differ significantly with regard to their
transcriptional activity, tissue distribution, andmode of regulation
(Shimano et al., 1997; Shimomura et al., 1997). Collectively,
SREBPs can activate the transcription of virtually all genes
involved in cholesterol, fatty acid, and phospholipid synthesis
(Horton et al., 2002), although a few instances of transcriptional
repression by SREBPs have also been described (Zeng et al.,
2004). Gene-expression studies support the notion that SREBP-
1a and -1c preferably activate transcription of genes involved in
fatty acid synthesis, whereas SREBP-2 displays some specificity
forgenes involved in cholesterol biosynthesis (Hortonet al., 1998),
However, sets of target genes are by no means mutually exclu-
sive, since SREBP-1a also activates genes critical for cholesterol
synthesis, andSREBP-2 regulates transcriptionof genes involved
in fatty acid synthesis (Horton et al., 2003). For example, both
SREBP-1a and SREBP-2 activate transcription of the genes
encoding fatty acid synthase and acetyl-CoA carboxylase 1,
which are essential for fatty acid synthesis. Likewise, both factors
activate transcription of the gene encoding the rate-limiting
enzyme of cholesterol synthesis, 3-hydroxy-3-methylglutaryl-
CoA (HMG-CoA) reductase (Horton et al., 2003). It should also
be noted that cellular cholesterol and fatty acid levels are not
only the result of denovobiosynthesis, but are strongly influenced
by uptake and export from cells (Nabel, 2003). To deliver fatty
acids and cholesterol to peripheral cells, the liver synthesizes
very low density lipoprotein (VLDL) particles. Removal of triacyl-
glycerol andcholesteryl esters eventually leads to the transforma-
tion of VLDL into LDL particles, which are cleared from circulation
via hepatic LDL receptor (LDLR). LDL cholesterol concentrations
are highly correlated with cardiovascular risk, and oxidation and/
or impaired clearance of LDL particles increase the risk of foam
cell and atheroma formation. In this regard, SREBP-1a and -2
directly activate hepatic transcription of the low-density lipopro-
tein (LDL) receptor, which allows the liver to increase its cellular
cholesterol content, and in parallel clears LDL particles from the
circulation (Horton et al., 2002; Yokoyama et al., 1993).
The activity of transcription factors is controlled by a my-
riad of mechanisms, including ligands and posttranslationalCell Metabolism 13, March 2, 2011 ª2011 Elsevier Inc. 241
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Figure 1. miR-33a Collaborates with SREBP-2 to Maintain Cellular
Lipid Homeostasis
(A) Traditional model of SREBP-2 function. SREBP-2 contains two transmem-
brane domains and is inserted in the membrane of the endoplasmic reticulum
(ER). Under conditions of abundant cholesterol (or phosphatidylethanolamine),
SREBP-2 is retained in the ER by a complex of SCAP and INSIG proteins.
When cholesterol levels fall, the interaction between INSIG and SCAP is
disrupted, allowing SCAP to interact with COPII-coated vesicles and target
SREBP-2 for export to the Golgi apparatus. Here, in two consecutive cleav-
ages by S1P and S2P, a transcriptionally competent N-terminal fragment is
released. After translocation to the nucleus, SREBP-2 induces expression of
genes involved in cholesterol and fatty acid synthesis, which serve to
normalize cellular lipid levels (modified from Ikonen [2008]).
(B) Integrated model for how the bifunctional SREBF-2 locus maintains lipid
homeostasis. After processing from an intron of SREBF2, miR-33a reduces
cellular cholesterol export by inhibiting expression of ABCA1 (and in themouse
ABCG1). In addition, miR-33a reduces mitochondrial fatty acid b-oxidation via
inhibition of HADHB, CROT, and CPT1A to increase intracellular lipid levels.
Thus the SREBF2 locus uses two distinct mechanisms to maintain lipid
homeostasis: regulated transcriptional activity of SREBP-2 and translational
repression by miR-33a.
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they initially reside in an inactive form, inserted into the
membrane of the endoplasmic reticulum via two transmembrane
domains (Figure 1A). To fulfil their transcriptional function,
SREBPs are proteolytically cleaved, freeing an N-terminal frag-
ment that translocates to the nucleus and activates transcription
of target genes (Goldstein et al., 2006; Horton et al., 2002). The
generation of transcriptionally active SREBP-2 is exquisitely
dependent upon content of cholesterol in the endoplasmic retic-
ulum (reviewed in Osborne and Espenshade, 2009). The acti-
vating proteolytic cleavage in the Golgi network only occurs if
SREBP-2 is transported from the endoplasmic reticulum
(Osborne and Espenshade, 2009). Export to the Golgi apparatus
is mediated by a SREBP-binding protein called SREBP
cleavage-activating protein (SCAP), which also binds to COPII-
coated vesicles, the cellular machinery that exports material
from endoplasmic reticulum to the Golgi. However, binding of
cholesterol to SCAP leads to conformational changes that
masks the binding site for COPII proteins and favors the interac-
tion with INSIG proteins, which reside exclusively within the
endoplasmic reticulum. Hence, high cholesterol levels retain
SCAP and SREBP in the endoplasmic reticulum and inhibit the
production of transcriptionally active SREBP in the Golgi. In
turn, the transcriptional targets of SREBP-1 and SREBP-2 act
to increase cellular cholesterol levels, which in a negative feed-
back loop inhibit proteolytic activation and transcription of
SREBPs. Hence, through an elegant mechanism, the activity of
transcription factors that regulate transcription of genes involved
in cholesterol synthesis is coupled to cellular cholesterol levels
(Figure 1A).
In addition to regulation by cholesterol, activation of SREBPs
by proteolysis is also dependent on hormones and other lipids.
For example, in the liver, insulin activates SREBP-1c, even in
the presence of high cholesterol levels, by suppressing expres-
sion of the endoplasmic reticulum docking protein, INSIG2a
(Yabe et al., 2003). In addition, interactions of oxysterols with
INSIG proteins stabilize binding to SCAP and thereby prevent
SREBP-1 and SREBP-2 movement to the Golgi for proteolysis
(Radhakrishnan et al., 2007).
An additional layer of complexity is added by the transcrip-
tional regulation of SREBF genes. SREBP-1c transcription is
activated by insulin signaling and the nuclear receptors for oxy-
sterols, liver X receptor a and b (LXR) (Shimomura et al., 1999);
(Repa et al., 2000). In turn, SREBPs increase the transcription
of SREBF2 in a positive feedback loop (Sato et al., 1996). Post-
translational activation of SREBP-2 therefore is paralleled by
induction of SREBP-2 mRNA (Figure 1A). Recent studies have
shown that the primary transcript of SREBP-2 also encodes
miR-33a, a microRNA that regulates cholesterol and fatty acid
metabolism, suggesting that transcriptional regulation of the
SREBF2 gene modulates the cellular capacity for producing
not only an active transcription factor, but also the expression
of miR-33a (Gerin et al., 2010b; Horie et al., 2010; Marquart
et al., 2010; Najafi-Shoushtari et al., 2010; Rayner et al., 2010).
Notably, the SREBF1 locus of primates and a limited number
of other species (excluding mice) encodes a closely related
miR-33 family member called miR-33b. Experimental data so
far are mainly available for miR-33a. We will therefore limit our
discussion to the function of miR-33a and will speculate how242 Cell Metabolism 13, March 2, 2011 ª2011 Elsevier Inc.the lack of miR-33b in mice might affect the lessons we can learn
from mouse models.
Role of miR-33a in Control of Cholesterol Metabolism
miRNAs are 21–24 nucleotide, non-coding RNAs, which are
important regulators of mRNA stability and translation. By
binding to partially complementary sites in the 30 untranslated
region (30UTR) of mRNA transcripts, miRNAs reduce translation
of these transcripts and/or lead to their degradation (Bartel,
Cell Metabolism
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cuous, and in some instances pairing of the six- to eight-nucle-
otide seed region of the miRNA to target transcripts is sufficient
for silencing (Bartel, 2009). Complementarity between miRNAs
and target genes, in conjunction with evolutionary conservation
of binding sites, is the basis for target site prediction algorithms
(Rajewsky, 2006), which support the notion that the majority of
protein-coding mRNA transcripts are regulated by miRNAs. In
fact, mRNA transcripts are often targeted by several different
miRNAs (Bartel, 2009), and proteomic studies demonstrate
that miRNAs fine-tune translation from many different target
transcripts (Selbach et al., 2008).
The human genome codes for more than 900 miRNAs.
Although produced from distinct genomic loci, some of these
miRNAs form families with similar or identical sequences. miRNA
families are predicted to bind and repress largely overlapping
sets of target transcripts, with functionality influenced by tissue-
and stimulus-specific expression of individual members. In
general, the potential for functional redundancy and combinato-
rial complexity in miRNA-mRNA regulatory circuits has
hampered the unequivocal assignment of physiological func-
tions to distinct miRNAs.
miRNAs are synthesized by RNA polymerase II as long
precursor transcripts containing hairpin loops, and two consec-
utive cleavages of these hairpins give rise to the mature form of
a miRNA (Bartel, 2009). A significant fraction of these precursor
transcripts also contain open-reading frames. In some
instances, proteins encoded by these open-reading frames
have related functions to the miRNAs. For example, the
PPARGC1B locus encodes both PGC-1b, a transcriptional
coactivator that regulates cellular energy metabolism, and in-
tronic miR-378/378*, which regulate lipid metabolism in adipo-
cytes and respiration in breast cancer cells (Eichner et al.,
2010; Gerin et al., 2010a). Recently, five independent groups
identified the SREBF2 gene as another example of a bifunctional
locus (Gerin et al., 2010b; Horie et al., 2010; Marquart et al.,
2010; Najafi-Shoushtari et al., 2010; Rayner et al., 2010)
(Figure 1B). In addition to the generation of SREBP-2 protein,
the SREBF2 locus contributes to lipid homeostasis by produc-
tion of miR-33a, which is processed from an intron within the
SREBF2 primary transcript (Figure 1B), and which has been
highly conserved during evolution from primitive chordates and
flies to vertebrates.
Although the recent focus on miR-33a was mainly sparked by
its interesting genomic localization (Gerin et al. 2010b; Horie
et al., 2010; Marquart et al., 2010; Najafi-Shoushtari et al.,
2010), miR-33a was studied by Rayner and colleagues after
observing its elevated expression in an unbiased screen for miR-
NAs regulated by depletion of cholesterol from human macro-
phages (Rayner et al., 2010). As confirmed by other groups,
they also reported reduced expression of miR-33a when macro-
phages were loaded with cholesterol using acetylated LDL (Mar-
quart et al., 2010; Rayner et al., 2010). In each case, changes in
miR-33a expression were closely paralleled by changes in
SREBP-2mRNA, lending further support for derivation of protein
and miRNA from the SREBF2 primary transcript. Whether under
certain circumstances miR-33a transcription, maturation, and/or
stability are regulated independently of SREBP-2 remains an
interesting, unanswered question.Another potential link to cholesterol was established when
investigators realized that several prediction algorithms sug-
gested binding sites for miR-33a in the 30UTRs of genes involved
in cholesterol transport, namely ATP-binding cassette A1
(ABCA1), ATP-binding cassette G1 (ABCG1), and Niemann-
Pick C1 (NPC1) (Gerin et al. 2010b; Horie et al., 2010; Marquart
et al., 2010; Najafi-Shoushtari et al., 2010; Rayner et al., 2010).
The ABCA1 and ABCG1 cholesterol transporters are membrane
proteins that mediate the export of cholesterol from peripheral
tissues to HDL particles (Figure 2A) and are critical for reverse
cholesterol transport to the liver (Rader et al., 2009; Yvan-Char-
vet et al., 2007). In the liver and intestine, ABCA1 plays an
additional role in de novo HDL synthesis by exporting cholesterol
onto apolipoprotein AI (ApoAI)-containing nascent HDL parti-
cles, which represents the first step in HDL biogenesis (Brunham
et al., 2006) (Figure 2A). Inactivation of both ABCA1 alleles in
humans leads to Tangier’s disease, which is characterized by
absence of HDL cholesterol and accumulation of cholesterol in
peripheral tissues (reviewed in Tang and Oram, 2009). In addi-
tion, variants of the ABCA1 locus are not only associated with
alterations in HDL levels, but also cardiovascular risk (Brunham
et al., 2008, 2009; Frikke-Schmidt et al., 2008). Thus, ABCA1
and ABCG1 are key regulators of cholesterol homeostasis.
The coordinate regulation of SREBP-2 mRNA and miR-33a
expression observed upon cholesterol depletion or loading of
macrophages is paralleled by strong inverse regulation of
ABCA1 mRNA and protein levels (Rayner et al., 2010). Although
transcriptional repression of ABCA1 by SREBP-2 protein may
contribute to this process (Zeng et al., 2004), overexpression
of miR-33a in a variety of in vitro systems suppresses ABCA1
mRNA and protein levels (Gerin et al. 2010b; Horie et al., 2010;
Marquart et al., 2010; Najafi-Shoushtari et al., 2010; Rayner
et al., 2010). In fact, endogenous miR-33a clearly plays a critical
regulatory role, because lentiviral expression of competitive
inhibitors or transfection with antisense oligonucleotides specific
for miR-33a increases ABCA1 protein levels (Figure 1B) (Gerin
et al. 2010b; Horie et al., 2010; Marquart et al., 2010; Najafi-
Shoushtari et al., 2010; Rayner et al., 2010). Regulation by
miR-33a is not limited to ABCA1 because overexpression of
this miRNA also decreases NPC-1, and in mouse cells ABCG1,
albeit to a lesser extent than ABCA1 (Najafi-Shoushtari et al.,
2010; Rayner et al., 2010). miRNAs generally regulate cellular
processes through relatively small changes to a great number
of proteins (Baek et al., 2008; Selbach et al., 2008); thus, it is
important to note whether the modest effects of miRs on protein
levels are functionally relevant. In this case, ectopic expression
ofmiR-33a in vitro robustly inhibits ApoAI-dependent cholesterol
export in a variety of cell culture models, whereas inhibition of
endogenous miR-33a increases cholesterol export (Figure 1B)
(Gerin et al. 2010b; Horie et al., 2010; Marquart et al., 2010; Na-
jafi-Shoushtari et al., 2010; Rayner et al., 2010).
Many of these observations have been confirmed and
extended using mice. Notably, inhibition of miR-33a by locked-
nucleic acid antisense oligonucleotides or by competitive
antagonists expressed from lentiviruses led to significant
increases in hepatic and macrophage ABCA1 expression, as
well as a 30%–50% increase in serumHDL cholesterol (Marquart
et al., 2010; Najafi-Shoushtari et al., 2010; Rayner et al., 2010)
(Figure 2B). Support for these findings came from Horie andCell Metabolism 13, March 2, 2011 ª2011 Elsevier Inc. 243
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macrophage and hepatic expression of ABCA1, and increased
baseline HDL cholesterol levels (Horie et al., 2010). Taken
together, these studies provide compelling evidence that miR-
33a plays a complementary but independent role to SREBP-2
in the maintenance of cellular cholesterol homeostasis, with
a potentially important role in the regulation of HDL cholesterol
levels (Figure 2). It should be noted that although increased
HDL cholesterol levels are consistent with increased reverse
cholesterol transport (Figure 2B), flux experiments are needed
to rigorously prove this point since it is the reverse cholesterol
transport and not steady-state HDL levels that are modulating
cardiovascular risk (Rader et al., 2009).
Although miR-33a has been studied almost exclusively in
hepatocytes and macrophages, its expression in most cell types
at readily detectable levels suggests that additional functions
remain to be discovered. Despite some disagreement in the
published works (Gerin et al. 2010b; Horie et al., 2010; Marquart
et al., 2010; Najafi-Shoushtari et al., 2010; Rayner et al., 2010),
miR-33a and SREBP-2 also appear to be highly expressed in
brain, adipose tissue and intestine. Organ-specific differences
of target gene regulation and expression may prove to be im-
portant. For example, the 30UTRs for mouse ABCG1 and NPC1
are targets of miR-33a in luciferase reporter assays (Marquart
et al., 2010; Najafi-Shoushtari et al., 2010; Rayner et al., 2010),
but fairly extensive investigation in mouse and human cell types
revealed repression of ABCG1 (and perhaps NPC1) protein by
endogenous miR-33a only in mouse macrophages (Rayner
et al., 2010). Thus, a more significant regulation of ABCG1 and
NPC1 by miR-33a in other cell types or organs should not yet
be discounted. In this context, regulation of ABCG1 is expected
to cooperate with alterations in ABCA1 to facilitate reverse
cholesterol transport (Yvan-Charvet et al., 2007). Although it is
clear that NPC1 is involved in recovery of cholesterol from
lysosomes, and that its loss leads to cholesterol accumulation
in liver, macrophages, and brain (Vance, 2010), the contribution
of NPC1 to the maintenance of intracellular cholesterol distribu-
tion, as well as its role in miR-33a function remains speculative.
Potential Roles for miR-33 in Fatty Acid Metabolism
It is curious that most invertebrate animals contain a conserved
miR-33, even though many of them are sterol auxotrophs
(Karlson, 1970). Furthermore, the lipids that control SREBP
processing are different between invertebrates and mammals.
For example, in Drosophila melanogaster, SREBP activation is
regulated by intermediates of the phospholipid synthesisFigure 2. Influence of miR-33a on HDL Cholesterol Levels
(A and B) miR-33a is generated from an intron of the SREBF2 primary transcript an
tive flux of cholesterol is denoted with red arrows under conditions of low sterol co
HDL synthesis requires ABCA1-dependent cholesterol secretion from the liver
accept cholesterol from ABCA1 and ABCG1 transporters. Hepatic uptake of HD
reverse cholesterol transport. To deliver fatty acids and cholesterol to peripheral
terol eventually leads to the transformation of VLDL into LDL particles, which ar
impaired clearance of LDL increase risk of foam cell formation and atheroma form
scription of genes involved in cholesterol synthesis (e.g., b-HMG CoA reductase
promote the expression of miR-33a, which inhibits the expression of ABCA1 and
and thereby prevents further decreases in intercellular sterol concentrations. miR
expression. In (B), suppression of miR-33a expression by either high sterol conce
expression, which potentially increases not only de novo synthesis of HDL partic
include a schematic representation of SREBP-2 expression in peripheral tissuespathway (i.e., phosphatidylethanolamine rather than cholesterol)
(Dobrosotskaya et al., 2002), and the primary transcriptional
targets of SREBP are genes involved in fatty acid and phospho-
lipid synthesis. It therefore seems reasonable to hypothesize that
the ancestral miR-33 might have regulated other aspects of lipid
metabolism, and that miR-33a may have retained some of these
functions. In fact, several genes involved in b-oxidation of fatty
acids contain predicted binding sites for miR-33a (Gerin et al.,
2010b). The mRNA transcripts targeted by miR-33a in reporter
assays include enzymes involved in b-oxidation of fatty acids
(i.e., the b-subunit of the mitochondrial trifunctional enzyme
HADHB) and proteins involved in the import of fatty acids into
mitochondria (i.e., carnitine palmitoyl-CoA transferase; CPT1A,
and carnitine octanoyl-CoA transferase; CROT) (Figure 1B).
Since the rate of b-oxidation is primarily controlled by the supply
of fatty acid substrates to mitochondria, it is notable that
miR-33a targets two transporters responsible for this rate-
limiting step. Overexpression of miR-33a in HepG2 cells inhibits
expression of CPT1A and HADHB proteins, decreases CROT
mRNA, reduces b-oxidation of fatty acids, and increases cellular
nonesterified fatty acids and triacylglycerol (Figure 1B) (Gerin
et al., 2010b). Notably, a predicted miR-33 binding site is
conserved in the transcript of the single CPT1 gene ofDrosophila
melanogaster, and reporter assays suggest that this site is func-
tional (Gerin et al., 2010b). In mouse models, no significant
changes of serum triacylglycerol levels have been observed
upon inactivation or inhibition of miR-33 (Horie et al., 2010;
Marquart et al., 2010; Najafi-Shoushtari et al., 2010; Rayner
et al., 2010). However, in these studies cellular triacylglycerol
levels in hepatocytes and macrophages were not measured.
Hence, further loss-of-function experiments in vitro and in vivo
will be needed to evaluate the physiological relevance of these
regulatory circuits.
What about miR-33b?
Mammalian genomes contain two SREBF genes encoding
SREBP-1a/c and SREBP-2, respectively, and in all of them,
SREBF2 contains a miR-33 family member (either miR-33 or
miR-33a). In contrast, only few species contain a miR-33 family
member (called miR-33b) in the SREBF1 gene. Similar to
miR-33b and SREBP-2, levels of miR-33b in human tissues
seem to be well correlated with levels of SREBP-1 mRNA levels.
Since miR-33a/SREBF2 and miR-33b/SREBF1 show differ-
ences in organ distribution and mode of regulation, it is possible
that when compared to rodents, the miR-33 family exerts addi-
tional functions in humans. Hence, results obtained in vivo ind inhibits translation of ABCA1 and ABCG1mRNAs, and perhaps NPC1. Puta-
ncentrations (A) or high sterol concentrations/miR-33a deficiency (B). De novo
and intestine into nascent HDL particles. In peripheral organs, HDL particles
L particles via the scavenger receptor-B1 (SR-B1) completes the process of
organs, the liver synthesizes VLDL particles. Delivery of fatty acids and choles-
e cleared from circulation via hepatic LDL receptor (LDLR). Oxidation and/or
ation. Upon reduction of hepatic cholesterol levels, SREBP-2 increases tran-
), as well as LDLR to increase uptake of LDL. In (A), low sterol concentrations
ABCG1 to suppress cholesterol export from liver, intestine, and macrophages
-33a may also influence subcellular cholesterol distribution by inhibiting NPC1
ntrations or experimental intervention results in increased ABCA1 and ABCG1
les but also loading with cholesterol in the periphery. For simplicity, we did not
and do not show effects of cholesterol synthesis and cholesterol secretion.
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directly transferable to the human system. It is interesting that
miR-33 and a single SREBF gene are conserved in some choles-
terol auxotroph animals, where the regulation of SREBP protein
and its transcriptional targets are centered around phospholipid
and fatty acid metabolism. Given the preference of SREBP-1 to
activate genes involved in fatty acid metabolism, it is tempting to
speculate that the function of ancestral miR-33 may have been
more related to miR-33b than miR-33a.
With regard to human disease, it should be noted that patients
withmetabolic syndrome and peripheral insulin resistance, show
increased expression of SREBP-1c in the liver (Kohjima et al.,
2008). If miR-33b in these cases is similarly increased, a consec-
utive downregulation of ABCA1 could explain a reduced HDL/
LDL cholesterol ratio in these patients. In addition, a potential
reduction of b-oxidation by miR-33b might contribute to the
development of hepatic steatosis. Future studies will explore
whether miR-33b plays a role in human disease and whether it
represents a target for therapeutic intervention.Conclusion
Given the integral role of HDL particles to reverse cholesterol
transport and the strong association between circulating HDL
and cardioprotection, the recent mechanistic insights into miR-
33a and cholesterol homeostasis could conceivably open
avenues for the development of novel therapeutics. However,
caveats to be noted include the fact that only a few miR-33a
targets have been identified, and many targets are likely. Thus,
pharmacological inhibition of miR-33a to influence metabolic
processes may lead to currently unanticipated side effects.
Moreover, although increased HDL cholesterol levels are associ-
ated with reduced cardiovascular mortality, elevating HDL levels
by pharmacological approaches (e.g., by cholesterol ester trans-
fer protein inhibitor) is not easily translated into cardiovascular
protection (Tall et al., 2008). Thus, the potential therapeutic utility
of altering miR-33a activity or levels awaits further in vivo exper-
imentation in large animal models where rates of reverse choles-
terol transport and development of atherosclerosis are included
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